Common In Vivo Applications of Clone 9D9 in Mice

Clone 9D9 is a monoclonal antibody targeting mouse CTLA4 (CD152), a key immune checkpoint that negatively regulates T cell activation. Its in vivo applications are primarily in the field of cancer immunotherapy, tumor microenvironment research, and mechanistic immunology studies in mice.

Cancer Immunotherapy

• Monotherapy and Combination Therapy: 9D9 is widely used to block CTLA4, thereby enhancing T cell activation and antitumor immunity. It has shown efficacy as both a standalone treatment and in combination with other immunotherapies, such as antiPD1/PDL1 agents, mirroring the clinical use of drugs like ipilimumab.
• Tumor Models: The antibody has been tested in various tumor models, including melanoma and colon cancer, where it demonstrates significant tumor growth control and, in some settings, complete tumor clearance.
• Dosing: Typical in vivo dosing is 100–250 µg per mouse, administered intraperitoneally every 3 days. Intratumoral injection has also been explored.

Tumor Microenvironment Studies

• Immune Cell Infiltration: 9D9 treatment increases global lymphocyte and specifically CD8+ T cell infiltration into tumors, along with upregulation of T cell activation markers (CD44, CD69, PD1).
• Regulatory T Cell (Treg) Modulation: Due to its mouse IgG2b isotype, 9D9 can deplete intratumoral Tregs, further enhancing antitumor immunity. Studies show a significant reduction in the proportion of CD4+CD25+FoxP3+ Tregs within treated tumors.
• Mechanistic Insights: By altering the balance of effector and regulatory T cells, 9D9 helps elucidate the role of CTLA4 in immune suppression within the tumor microenvironment.

Alternative Delivery Methods

• DNAEncoded Antibody (DMAb) Platforms: 9D9 has been delivered via DNA plasmids, enabling in vivo production of the antibody after intramuscular electroporation. This approach achieves therapeutic levels of antibody in the serum and demonstrates efficacy in controlling tumor growth, offering a versatile platform for antibody delivery in preclinical studies.

Additional Applications

• Functional Assays: Beyond tumor models, 9D9 is used in assays to study biological pathways affected by CTLA4, including pharmacokinetic (PK) and antidrug antibody (ADA) assays.
• Tool for Immunological Research: As a surrogate for human CTLA4 blockade, 9D9 is instrumental in preclinical studies aiming to understand checkpoint inhibition and optimize combination regimens.

Summary Table: Key In Vivo Applications of 9D9

Conclusion

Clone 9D9 is a cornerstone tool in mouse immunology and cancer research, primarily for studying CTLA4 blockade, enhancing antitumor immunity, modulating the tumor microenvironment, and testing novel antibody delivery platforms. Its ability to deplete Tregs and promote CD8+ T cell activity makes it especially valuable for understanding and improving cancer immunotherapy strategies.

In the literature, antibodies or proteins commonly used alongside the 9D9 monoclonal antibody, which targets mouse CTLA4, include:

• Ipilimumab and Tremelimumab: These are human CTLA4 targeting antibodies often referenced in studies for comparison or combination therapy with 9D9.
• PD1/PDL1 Pathway Targeting Antibodies: While not specifically paired with 9D9, these are used in broader immune checkpoint studies, including combination therapies with antiCTLA4 antibodies like ipilimumab to enhance antitumor responses.
• Other antimouse CTLA4 clones: Such as 9H10 and 4F10, which are also used in mouse models for CTLA4 blockade studies.

These antibodies and proteins are used in various research contexts, including cancer immunotherapy models, to better understand the mechanisms of CTLA4 blockade and to develop more effective treatments.

Clone 9D9 is a widely used antimouse CTLA4 monoclonal antibody with significant impact in immunooncology research. Key findings from scientific literature on 9D9 reveal that:

• 9D9 promotes antitumor immune responses by increasing lymphocyte and CD8+ T cell infiltration into tumors, elevating activation markers (CD44, CD69, PD1) on T cells, and reducing the proportion of regulatory T cells (Tregs; CD4+/CD25+/FoxP3+), resulting in tumor regression.

• The therapeutic efficacy of 9D9 depends on its ability to both antagonize CTLA4 signaling and deplete intratumoral Tregs. Studies directly comparing 9D9 with nonantagonistic constructs show that while both can deplete Tregs, only 9D9 enhances T cell activation, T cell priming in tumordraining lymph nodes, and achieves higher rates of longterm tumor cures in mouse models.

• Expression optimization in DNAencoded monoclonal antibody systems has been achieved for 9D9, significantly increasing antibody yield in vitro and in vivo without compromising CTLA4 binding specificity or efficacy.

• Mechanistic insights demonstrate that 9D9’s antitumor activity is not solely due to Treg depletion; CTLA4 antagonism is required for optimal T cell priming and maximum survival benefit. When 9D9’s Fc region is silenced, it loses therapeutic efficacy, confirming the necessity of both Treg depletion and checkpoint blockade.

• Comparative studies have found differences among antiCTLA4 clones (e.g., 9D9, 9H10, UC104F1011), with 9D9 excelling in intratumoral Treg depletion and immune activation.

In summary, clone 9D9’s unique capability to combine CTLA4 antagonism with effective Treg depletion leads to enhanced T cell activation and robust antitumor immunity, supporting its use in studies of immune checkpoint blockade and cancer immunotherapy.

Dosing regimens of clone 9D9 (antiCTLA4) show remarkable consistency across different mouse models, though specific applications have introduced some variations in administration routes and frequencies.

The standard dosing approach for clone 9D9 uses 100250 μg per mouse administered via intraperitoneal injection every 3 days. This range has become the established protocol across most cancer immunotherapy studies. The specific dose within this range often depends on the experimental objectives and tumor model being studied.

Route of Administration

While intraperitoneal injection represents the primary delivery method, clone 9D9 has also been tested via intratumoral administration in certain experimental designs. This flexibility in delivery routes reflects the antibody's versatility in different research contexts, though intraperitoneal remains the most commonly reported approach.

Timing and Schedule

The every3day dosing schedule appears consistently across various mouse models. This frequency has been optimized to maintain therapeutic antibody levels while allowing for effective checkpoint blockade. In some protocols, treatment begins as early as 3 days after tumor implantation, demonstrating the antibody's utility in earlystage disease models.

Combination Therapy Contexts

Clone 9D9 is frequently employed in combination therapy studies, where it's paired with antiPD1 or antiPDL1 antibodies. In these combination regimens, the dosing typically remains within the standard 100250 μg range. Multipledose pharmacokinetic studies have shown that when administered at 110 mg/kg twice weekly, clone 9D9 demonstrates a notably long terminal halflife, approximately fivefold longer than some comparator antibodies, leading to greater than twofold accumulation over repeated dosing cycles.

Unique Functional Properties

An important consideration for clone 9D9 across different models is its dual mechanism of action. Due to its mouse IgG2b Fc domain, this clone not only blocks CTLA4 but also depletes intratumoral regulatory T cells (Tregs), which enhances its antitumor immunity effects. This property distinguishes it from other antiCTLA4 clones and may influence dosing decisions in specific experimental contexts.